Literature DB >> 33526481

Optimizing Aminoglycoside Dosing Regimens for Critically Ill Pediatric Patients with Augmented Renal Clearance: a Convergence of Parametric and Nonparametric Population Approaches.

Sean N Avedissian1, Roxane Rohani2,3, John Bradley4,5, Jennifer Le6, Nathaniel J Rhodes7,3.   

Abstract

Augmented renal clearance (ARC) can occur in critically ill pediatric patients receiving aminoglycosides such as gentamicin and tobramycin, yet optimal dosing strategies for ARC are undefined. We evaluated the probability of achieving efficacious or toxic exposures in pediatrics. Parallel population modeling of concentration strategies were pursued using Pmetrics v1.5.2 (nonparametric) and Monolix v2019R2 (parametric). Bayesian exposures were used to classify ARC based on total clearance (CL). The effects of serum creatinine (SCR), creatinine clearance (CRCL), total body weight (TBW), postnatal age (PNA), and ARC were explored as covariates. The probabilities of target attainment (PTA) (i.e., maximum concentration [C max]/MIC, area under the concentration-time curve [AUC]/MIC) and of toxic exposure (PTE) (i.e., minimum concentration [C min] > 2 μg/ml) were calculated according to PNA and ARC. A total of 123 patients (1 to 21 years old, 56% female) contributed 304 concentrations. A two-compartment model was superior to a one-compartment model in both approaches. Bayesian posterior predicted concentrations from the nonparametric base model fit the data well (R 2 = 0.96) and classified 34 patients as having ARC (28%). Both the nonparametric and parametric approaches resulted in allometrically scaling of TBW on volume (V) and clearance (CL). ARC modified CL and central V. CRCL and a maturation function modified CL. ARC was associated with a 1.49- versus 1.66-fold increase in CL and a 1.56- versus 1.66-fold increase in the central V (nonparametric versus parametric). A high dose of 12 mg/kg of body weight/day was required to achieve adequate PTA when MICs were 1 to 2 μg/ml; ARC lowered achievable MICs. When PNA was <2 years, PTE was increased. Aminoglycoside monotherapy should be avoided in critically ill pediatric patients with ARC when MICs exceed 1 μg/ml, as optimal exposures are unachievable with standard dosing.
Copyright © 2021 American Society for Microbiology.

Entities:  

Keywords:  aminoglycosides; augmented renal clearance; population-based pharmacokinetic modeling

Year:  2021        PMID: 33526481      PMCID: PMC8097479          DOI: 10.1128/AAC.02629-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  40 in total

1.  Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations*.

Authors:  Andrew A Udy; João P Baptista; Noelle L Lim; Gavin M Joynt; Paul Jarrett; Leesa Wockner; Robert J Boots; Jeffrey Lipman
Journal:  Crit Care Med       Date:  2014-03       Impact factor: 7.598

2.  Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity.

Authors:  M J Rybak; B J Abate; S L Kang; M J Ruffing; S A Lerner; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

3.  Augmented renal clearance: a common condition in critically ill children.

Authors:  Tatjana Van Der Heggen; Evelyn Dhont; Harlinde Peperstraete; Joris R Delanghe; Johan Vande Walle; Peter De Paepe; Pieter A De Cock
Journal:  Pediatr Nephrol       Date:  2019-02-18       Impact factor: 3.714

4.  Augmented Renal Clearance in Critically Ill Patients: A Systematic Review.

Authors:  Idoia Bilbao-Meseguer; Alicia Rodríguez-Gascón; Helena Barrasa; Arantxazu Isla; María Ángeles Solinís
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

Review 5.  Augmented Renal Clearance.

Authors:  Aaron M Cook; Jimmi Hatton-Kolpek
Journal:  Pharmacotherapy       Date:  2019-03-11       Impact factor: 4.705

Review 6.  Pharmacokinetic issues for antibiotics in the critically ill patient.

Authors:  Jason A Roberts; Jeffrey Lipman
Journal:  Crit Care Med       Date:  2009-03       Impact factor: 7.598

7.  Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs.

Authors:  Sylvain Goutelle; Laurent Bourguignon; Pascal H Maire; Michael Van Guilder; John E Conte; Roger W Jelliffe
Journal:  Antimicrob Agents Chemother       Date:  2009-04-20       Impact factor: 5.191

8.  Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy.

Authors:  Barbara O M Claus; Eric A Hoste; Kirsten Colpaert; Hugo Robays; Johan Decruyenaere; Jan J De Waele
Journal:  J Crit Care       Date:  2013-05-14       Impact factor: 3.425

9.  Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian.

Authors:  Tatiana Tatarinova; Michael Neely; Jay Bartroff; Michael van Guilder; Walter Yamada; David Bayard; Roger Jelliffe; Robert Leary; Alyona Chubatiuk; Alan Schumitzky
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-02-13       Impact factor: 2.745

10.  Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury.

Authors:  Ravindra L Mehta; John A Kellum; Sudhir V Shah; Bruce A Molitoris; Claudio Ronco; David G Warnock; Adeera Levin
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

View more
  1 in total

Review 1.  Clinical Pharmacokinetics of Gentamicin in Various Patient Populations and Consequences for Optimal Dosing for Gram-Negative Infections: An Updated Review.

Authors:  Caspar J Hodiamont; Annemieke K van den Broek; Suzanne L de Vroom; Jan M Prins; Ron A A Mathôt; Reinier M van Hest
Journal:  Clin Pharmacokinet       Date:  2022-06-27       Impact factor: 5.577

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.